Preschool CGM Use and Glucose Variability in Type 1 Diabetes
The Effect of Continuous Glucose Monitoring Use on Glucose Variability in Preschool Children With Type 1 Diabetes
The objectives of this clinical study is to evaluate the efficacy continuous glucose monitoring (CGM) use on glucose variability (GV) in preschool children with T1D treated with CSII.
Downloads from CGM and CSII saved in pdf from will be retrospectively reviewed and analysed for all preschool children with type 1 diabetes in Slovenia. Glucose variability and other glycemic parameters will be analyzed separately for periods when CGM was used (CGM and SMBG data) and compared to periods when CGM was not used (SMBG only data).
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Ljubljana, Slovenia, 1000
- UMC - University Children's Hospital Ljubljana
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subject with Type 1 diabetes (> 6 months since diagnosis)
- Insulin infusion pump CSII therapy for at least 3 months
- Age ≤ 7 years
- HbA1c at inclusion ≥ 6.5 and < 10
- BMI SDS - below the 95th percentile for age
Exclusion Criteria:
- Concomitant diseases that influence metabolic control
- Participation in any other interventional study
- Known or suspected allergy to trial products
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Cross-Sectional
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glucose variability
Time Frame: Three years
|
Glucose variability as SD and CV of glucose levels measured with CGM and blood glucose
|
Three years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean intersticial glucose
Time Frame: Three years
|
Mean glucose as measured with CGM
|
Three years
|
|
Mean blood glucose
Time Frame: Three years
|
Mean glucose as measured with SMBG
|
Three years
|
|
HbA1c
Time Frame: Three years
|
glycosilated hemoglobin
|
Three years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CGM-GV-Preschool- SI-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
NCT06783309RecruitingType 1 Diabetes | Type 1 Diabetes Mellitus | T1DM | T1D | Type 1 Diabetes in Adolescence | Type 1 Diabetes in Children | Type 1 Diabetes Patients | Type 1 Diabetes Mellitis | T1DM - Type 1 Diabetes Mellitus | Type 1 Diabetes (Juvenile Onset)
-
NCT07427134Not yet recruitingType 1 Diabetes Mellitus | T1DM | Type 1 Diabetes Mellitus (T1DM) | T1DM - Type 1 Diabetes Mellitus
-
NCT06676566Enrolling by invitationType 1 Diabetes Mellitus | Stage 2 Type 1 Diabetes | Stage 1 Type 1 Diabetes | Stage 3 Type 1 Diabetes
-
NCT07336459Active, not recruitingType 2 Diabetes Mellitus 1
-
NCT03211858CompletedType 1 Diabetes Mellitus-Type 2 Diabetes Mellitus
-
NCT07493122Not yet recruitingType 1 Diabetes | Diabetes Type 1 | Type 1 Diabetes (T1D)
-
NCT07610213Not yet recruitingType 1 Diabetes Mellitus | Autoimmune Diabetes | Type 1 Diabetes Mellitus (T1DM)
-
NCT01781975CompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDM
-
NCT05168657CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1
-
NCT00229658CompletedType 2 Diabetes Mellitus | Type 1 Diabetes Mellitus
Clinical Trials on CGM ON
-
NCT05336214CompletedDiabetes Mellitus, Type 2 | Diabetes Mellitus, Type 1 | Continuous Glucose Monitoring
-
NCT07599072RecruitingInsulin Resistance | Obesity & Overweight | Pre Diabetic
-
NCT05941286Completed
-
NCT07006480Recruiting
-
NCT02583776CompletedInfant, Very Low Birth Weight | Neonatal Hypoglycemia
-
NCT07007676Recruiting
-
NCT02282397Completed
-
NCT03353415CompletedHypoglycemia | Hypoglycemia, Reactive